Novel mAb contraceptive + TDF IVR
Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Intravaginal - Intravaginal Ring (IVR)
Mechanism of Action:
Nucleoside analogue reverse transcriptase inhibitor (NRTI) and sperm agglutinating antibody
Developer:
- Oak Crest Institute of Science
- University of North Carolina, Chapel Hill
Funding:
- Nat. Institute Child Health & Human Development (NICHD)
Funding Mechanism:
NICHD: R01
Active Ingredient(s):
- Monoclonal Antibodies
- Tenofovir Disoproxil Fumarate (TDF)
Product Indication(s):
- HIV
- Pregnancy